Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis

Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for Treatment of Psoriasis

This is an observational safety study tracking psoriasis patients on etanercept (Enbrel) for 5 years.

This is a prospective, multi-center, observational surveillance registry to evaluate data on the long-term safety of etanercept (Enbrel) use in the treatment of psoriasis.

Inclusion Criteria:

• Patients with plaque psoriasis

Exclusion Criteria:

• Prior exposure to any tumor necrosis factor (TNF)-inhibitor
• Patients for whom Enbrel is contraindicated
• Patients currently enrolled in or has not yet completed at least 30 days since ending other investigational drug study.